Enlivex deployed $10 million to acquire more than 3 billion RAIN tokens after completing roughly $21 million in financing. The purchase price was $0.0033 per token, which the company said represented a 62% discount to recent market levels. The move adds digital assets to its treasury strategy and gives the firm direct exposure to decentralized prediction markets.
A discounted entry into Arbitrum-based prediction market infrastructure
Rain protocol operates as a decentralized infrastructure layer on Arbitrum and supports prediction markets across multiple blockchain networks. Enlivex tied its investment to that segment, where activity has picked up over the past year. The company’s position is not limited to the tokens already purchased.
Under the same terms, Enlivex also secured the right to buy up to 272 billion additional RAIN tokens through December 2027. That option gives the company room to adjust its exposure over time as conditions change across the digital asset market. The scale is unusually large, and the time window is long.
Net proceeds totaled about $18.7 million after costs
According to the article, net proceeds from the financing came to about $18.7 million after costs. The funding was arranged through a convertible note agreement with The Lind Partners. The deal included a fixed conversion price of $2.69175 per share of Enlivex equity, a level the article said was above the company’s recent stock price.
Management plans to direct capital toward both pharmaceutical programs and digital asset initiatives. Enlivex is continuing work on its lead immunotherapy candidate, Allocetra, while building a position in crypto prediction markets. Its board also approved a $20 million share buyback program, giving the company added flexibility in how it allocates capital.
RAIN rose after the announcement as clinical progress continued
Following the financing and token purchase announcement, RAIN moved higher before settling near $0.0088, close to its prior trading range. Enlivex shares closed slightly lower during regular trading and then moved up in after-hours trading. The source noted that the stock had still posted an overall year-to-date gain despite volatility.
On the pharmaceutical side, Enlivex also reported a regulatory step forward for Allocetra. The company received approval to proceed with a Phase 2b clinical trial focused on patients with moderate to severe knee osteoarthritis. That leaves Enlivex operating on two tracks at once: drug development and balance-sheet exposure to blockchain-based prediction market infrastructure.